Funatsu T - Search Results

1

[Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].

Hirata T, Funatsu T, Keto Y, Akuzawa S, Akiho H, Nishida A, Sasamata M, Miyata K. Hirata T, et al. Among authors: funatsu t. Nihon Yakurigaku Zasshi. 2009 May;133(5):281-91. doi: 10.1254/fpj.133.281. Nihon Yakurigaku Zasshi. 2009. PMID: 19443966 Review. Japanese. No abstract available.

2

Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.

Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M. Hirata T, et al. Among authors: funatsu t. J Pharmacol Sci. 2007 Jul;104(3):263-73. doi: 10.1254/jphs.fp0070620. J Pharmacol Sci. 2007. PMID: 17652911 Free article.

3

Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.

Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M. Funatsu T, et al. Eur J Pharmacol. 2007 Nov 14;573(1-3):190-5. doi: 10.1016/j.ejphar.2007.06.041. Epub 2007 Jul 3. Eur J Pharmacol. 2007. PMID: 17658508

4

Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents.

Hirata T, Funatsu T, Keto Y, Akuzawa S, Sasamata M, Miyata K. Hirata T, et al. Among authors: funatsu t. J Pharmacol Sci. 2008 Feb;106(2):264-70. doi: 10.1254/jphs.fp0071943. J Pharmacol Sci. 2008. PMID: 18296863 Free article.

5

Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.

Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M. Hirata T, et al. Among authors: funatsu t. Inflammopharmacology. 2007 Feb;15(1):5-9. doi: 10.1007/s10787-006-1537-1. Inflammopharmacology. 2007. PMID: 17323187 Review.

6

Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.

Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K. Hirata T, et al. Among authors: funatsu t. Eur J Pharmacol. 2008 Jun 10;587(1-3):281-4. doi: 10.1016/j.ejphar.2008.03.040. Epub 2008 Mar 30. Eur J Pharmacol. 2008. PMID: 18456254

7

Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer.

Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K. Hirata T, et al. Among authors: funatsu t. Neurogastroenterol Motil. 2008 May;20(5):557-65. doi: 10.1111/j.1365-2982.2007.01069.x. Epub 2008 Jan 21. Neurogastroenterol Motil. 2008. PMID: 18221252

8

Mucosal acid causes gastric mucosal microcirculatory disturbance in nonsteroidal anti-inflammatory drug-treated rats.

Funatsu T, Chono K, Hirata T, Keto Y, Kimoto A, Sasamata M. Funatsu T, et al. Eur J Pharmacol. 2007 Jan 5;554(1):53-9. doi: 10.1016/j.ejphar.2006.10.023. Epub 2006 Oct 18. Eur J Pharmacol. 2007. PMID: 17112499

9

[Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].

Funatsu T, Kakuta H, Tanaka H, Arai Y, Suzuki K, Miyata K. Funatsu T, et al. Nihon Yakurigaku Zasshi. 2001 Jan;117(1):65-76. doi: 10.1254/fpj.117.65. Nihon Yakurigaku Zasshi. 2001. PMID: 11233299 Review. Japanese.

10

Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.

Funatsu T, Kakuta H, Takasu T, Miyata K. Funatsu T, et al. Eur J Pharmacol. 2002 Nov 29;455(2-3):161-7. doi: 10.1016/s0014-2999(02)02611-0. Eur J Pharmacol. 2002. PMID: 12445582

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

362 results

Search Page